Literature DB >> 17296647

Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension.

Monique N Pratt-Ubunama1, Mari K Nishizaka, Robyn L Boedefeld, Stacey S Cofield, Susan M Harding, David A Calhoun.   

Abstract

OBJECTIVE: Obstructive sleep apnea (OSA) and primary aldosteronism are common in subjects with resistant hypertension; it is unknown, however, if the two disorders are causally related. This study relates plasma aldosterone and renin levels to OSA severity in subjects with resistant hypertension, and in those with equally severe OSA but without resistant hypertension serving as control subjects.
METHODS: Seventy-one consecutive subjects referred to the University of Alabama at Birmingham (UAB) for resistant hypertension (BP uncontrolled on three medications) and 29 control subjects referred to UAB Sleep Disorders Center for suspected OSA were prospectively evaluated by an early morning plasma aldosterone concentration (PAC) and renin level, and by overnight, attended polysomnography.
RESULTS: OSA (apnea-hypopnea index [AHI] > or = 5/h) was present in 85% of subjects with resistant hypertension. In these subjects, PAC correlated with AHI (rho = 0.44, p = 0.0002) but not renin concentration. Median PAC was significantly lower in control subjects compared to subjects with resistant hypertension (5.5 ng/dL vs 11.0 ng/dL, p < 0.05) and not related to AHI. In male subjects compared to female subjects with resistant hypertension, OSA was more common (90% vs 77%) and more severe (median AHI, 20.8/h vs 10.8/h; p = 0.01), and median PAC was significantly higher (12.0 ng/dL vs 8.8 ng/dL, p = 0.006).
CONCLUSION: OSA is extremely common in subjects with resistant hypertension. A significant correlation between PAC and OSA severity is observed in subjects with resistant hypertension but not in control subjects. While cause and effect cannot be inferred, the data suggest that aldosterone excess may contribute to OSA severity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296647     DOI: 10.1378/chest.06-1442

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  112 in total

1.  Sleep and hypertension.

Authors:  David A Calhoun; Susan M Harding
Journal:  Chest       Date:  2010-08       Impact factor: 9.410

Review 2.  Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management.

Authors:  Stephen K Williams; Joseph Ravenell; Girardin Jean-Louis; Ferdinand Zizi; James A Underberg; Samy I McFarlane; Gbenga Ogedegbe
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

3.  Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.

Authors:  Carolina C Gonzaga; Krishna K Gaddam; Mustafa I Ahmed; Eduardo Pimenta; S Justin Thomas; Susan M Harding; Suzanne Oparil; Stacey S Cofield; David A Calhoun
Journal:  J Clin Sleep Med       Date:  2010-08-15       Impact factor: 4.062

4.  Does continuous positive airway pressure reduce aldosterone levels in patients with obstructive sleep apnea?

Authors:  Si-Jiu Yang; Xing-Tang Jiang; Xiao-Bin Zhang; Xiao-Wen Yin; Wei-Xian Deng
Journal:  Sleep Breath       Date:  2016-01-15       Impact factor: 2.816

5.  Aldosterone receptor antagonists: effective but often forgotten.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

Review 6.  Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.

Authors:  Badhma Valaiyapathi; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

Review 7.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

Review 8.  Obstructive sleep apnea, hypertension and cardiovascular diseases.

Authors:  C Gonzaga; A Bertolami; M Bertolami; C Amodeo; D Calhoun
Journal:  J Hum Hypertens       Date:  2015-03-12       Impact factor: 3.012

9.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

10.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.